Organization

APOLLO CLINICAL LABORATORIES INC.

According to 2025 Medicare claims, APOLLO CLINICAL LABORATORIES INC. (NPI: 1952876203) practices clinical laboratory (billing independently) in the New York-Jersey City-White Plains, NY-NJ market, with the plurality of this provider's patient population coming from Hudson, NJ. This provider's primary affiliated billing organization is APOLLO CLINICAL LABORATORIES INC. (NPI: 1952876203) and primary practice location at 07083-0883.

The organization's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,091 traditional Medicare patients, billed 5,078 HCPCS/CPT codes, and received $689,001 in Medicare payments. The top billing code was G0483 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, this provider has fewer than 5 years of reported Part D prescription costs data, so a reliable trend cannot be assigned. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$611K$1.2M2019 Medicare payment: $352,201 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $790,043 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $1,221,448 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $1,142,460 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $825,897 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $689,001 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
20198451,762$352,201
20201,3503,743$790,043
20212,69214,765$1,221,448
20222,26414,500$1,142,460
20231,3676,084$825,897
20241,0915,078$689,001

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

No connected Part D records

No connected Part D records

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
G0483Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms6591,474$242
G0482Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms109129$195
G0481Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms226335$153
G0480Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms2271,260$112
80307Testing for presence of drug, by chemistry analyzers5711,880$61

Top 5 Part D drugs in 2024

By total drug costs.

No connected Part D drug-level records for 2024.

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for APOLLO CLINICAL LABORATORIES INC.?

Tedicare shows public-source Medicare data for APOLLO CLINICAL LABORATORIES INC. (NPI 1952876203), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does APOLLO CLINICAL LABORATORIES INC. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to APOLLO CLINICAL LABORATORIES INC.?

APOLLO CLINICAL LABORATORIES INC. is linked to APOLLO CLINICAL LABORATORIES INC. (billing NPI 1952876203) in the available physician profile data.

Does APOLLO CLINICAL LABORATORIES INC. have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.